

1
2 **A pilot study to identify blood-based markers associated with**
3 **response to treatment with Vedolizumab in patients with Inflammatory**
4 **Bowel Disease.**

5
6 **Short title: Markers of treatment response to vedolizumab**

7
8 **Author list**

9 John D. Rioux, PhD ^{1,2,*}, Gabrielle Boucher, MSc ¹, Anik Forest, MSc ¹, Bertrand Bouchard, MSc
10 ¹, Lise Coderre, PhD ³, Caroline Daneault, MSc ¹, Isabelle Robillard Frayne, MSc ¹, Julie
11 Thompson Legault, MSc ¹, iGenoMed Consortium, Alain Bitton, MD ⁴, Ashwin Ananthakrishnan,
12 MD ^{5,6}, Sylvie Lesage, PhD ^{3,7}, Ramnik J. Xavier, MD ^{5,6}, Christine Des Rosiers, PhD ^{1,8}.

13
14 **Affiliations**

- 15 1- Montreal Heart Institute Research Center, Montreal, Quebec, Canada;
16 2- Université de Montréal, Faculty of Medicine, Montreal, Quebec, Canada;
17 3- Maisonneuve-Rosemont Hospital Research Center, Montréal, Québec, Canada;
18 4- McGill University Health Centre, Division of Gastroenterology, Montreal, Quebec,
19 Canada;
20 5- Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA;
21 6- Harvard Medical School, Boston, MA, USA;
22 7- Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal,
23 Montréal, Québec, Canada;
24 8- Département de Nutrition, Université de Montréal, Montréal, Québec, Canada

25
26 *** Address correspondence to:** John D. Rioux, PhD, Montreal Heart Institute, Research Center,
27 5000 Bélanger, Montréal, Québec, H1T 1C8, Canada. TEL: (514) 376-3330 x3741 EMAIL:
28 (john.david.rioux@umontreal.ca)

29
30
31

32

33

34

35 **ABSTRACT**

36

37 The inflammatory bowel diseases (IBD) known as Crohn's disease (CD) and ulcerative colitis
38 (UC) are chronic inflammatory diseases of the gastrointestinal tract believed to arise because of
39 an imbalance between the epithelial, immune and microbial systems. It has been shown that
40 biological differences (genetic, epigenetic, microbial, environmental, etc.) exist between patients
41 with IBD, with multiple risk factors been associated with disease susceptibility and IBD-related
42 phenotypes (e.g. disease location). It is also known that there is heterogeneity in terms of
43 response to therapy in patients with IBD, including to biological therapies that target very
44 specific biological pathways (e.g. TNF-alpha signaling, IL-23R signaling, immune cell trafficking,
45 etc.). It is hypothesized that the better the match between the biology targeted by these
46 advanced therapies and the predominant disease-associated pathways at play in each patient
47 will favor a beneficial response. The aim of this pilot study was to identify potential biological
48 differences associated with differential treatment response to the anti $\alpha 4\beta 7$ integrin therapy
49 known as Vedolizumab. Our approach was to measure a broad range of analytes in the serum
50 of patients prior to initiation of therapy and at the first clinical assessment visit, to identify
51 potential markers of biological differences between patients at baseline and to see which
52 biomarkers are most affected by treatment in responders. Our focus on early clinical response
53 was to study the most proximal effects of therapy and to minimize confounders such as loss of
54 response that occurs further distal to treatment initiation. Specifically, we performed targeted
55 analyses of >150 proteins and metabolites, and untargeted analyses of >1100 lipid entities, in
56 serum samples from 92 IBD patients (42 CD, 50 UC) immediately prior to initiation of therapy
57 with vedolizumab (baseline samples) and at their first clinical assessment (14-week samples).
58 We found lower levels of SDF-1a, but higher levels of PDGF- $\beta\beta$, lactate, lysine, phenylalanine,

59 branched chain amino acids, alanine, short/medium chain acylcarnitines, and triglycerides
60 containing myristic acid in baseline serum samples of responders as compared to non-
61 responders. We also observed an increase in serum levels of CXCL9 and citrate, as well as a
62 decrease in IL-10, between baseline and week 14 samples. In addition, we observed that a
63 group of metabolites and protein analytes was strongly associated with both treatment response
64 and BMI status, although BMI status was not associated with treatment response.

65

66

67 **Keywords:** vedolizumab, crohn's disease, ulcerative colitis, biomarkers, treatment response

68

69

70

71

72

73 INTRODUCTION

74 The inflammatory bowel diseases (IBD) are chronic relapsing inflammatory diseases of the
75 gastrointestinal tract that affect over one million Americans. The current “Therapeutic Pyramid”
76 approach to IBD treatment aims to prescribe the mildest therapies first, and then for non-
77 responders, progressively intensify to agents with greater therapeutic effect (e.g. biologics) but
78 at significantly greater cost. Recently, there has been a shift in this treatment paradigm whereby
79 biologics are being considered earlier (1, 2). Distinguishing in advance patients who will respond
80 to biologics from non-responders would lead to improved therapeutic response rates, better
81 outcomes for patients, decreased complications and adverse events, less tissue damage, and a
82 decrease in societal costs. Currently, there are no reliable tools that enable us to match
83 individual patients with the appropriate therapy. This will become an even greater problem with
84 multiple new biologics and small molecules expected on the market in the coming years.

85
86 To meet this important challenge, numerous studies seeking biomarkers that predict response
87 to advanced therapies in IBD have been performed using serum/plasma, fecal or biopsy
88 samples. These studies support the need and feasibility of finding biomarkers associated with
89 response to advanced therapies in IBD however, most restricted their analyses to a single
90 biomarker type. For example, several SNPs are associated with non-response versus durable
91 response to anti-TNF therapy (3, 4). Immune-assay-based stratification has also seen some
92 success (5, 6). Functional assays using the agent or its target have also provided information
93 regarding the likelihood of response (7). Biomarker discovery attempts have also been made
94 with biopsies with good success for example high pre-treatment expression of oncostatin M was
95 strongly associated with anti-TNF therapy failure (8, 9).

96
97 In the current study, we focus on the response to treatment with vedolizumab, as it has a
98 mechanism of action quite distinct from other advanced therapies. Rather than block cytokine
99 signaling, vedolizumab is believed to interfere with immune cell trafficking to the intestines.
100 Specifically, vedolizumab is an antibody that is specific to $\alpha 4\beta 7$ integrin and was designed to
101 block its binding to MAdCAM-1, which is expressed on venular endothelium. While it was
102 originally designed to block T-cell trafficking to the inflamed intestinal tissue, more recent
103 studies suggest other potential mechanisms such as blocking the trafficking of pro-inflammatory
104 macrophages and/or dendritic cells to the gut, or by skewing the macrophage population away
105 from a pro-inflammatory phenotype to a wound healing phenotype (10, 11).

106

107 While beyond the scope of this pilot project, our ultimate objective is to develop a biomarker
108 panel to facilitate therapeutic decisions in the clinic, we thus chose to prioritize blood-based
109 biomarker discovery for the easiest integration within clinical practice. The cohort consisted of
110 42 CD and 50 UC patients where Vedolizumab had been administered intravenously at weeks
111 0, 2, 6 and 14, and serum samples collected at weeks 0 and 14 (12). Assessment of treatment
112 response was performed using standardized clinical scores: Harvey Bradshaw Index (HBI) for
113 patients with Crohn's disease and the simple clinical colitis activity index (SCCAI) (13, 14).
114 Serum samples were evaluated for the level of a targeted set of 49 cytokines, chemokines, and
115 growth factors, many of which were previously shown to be elevated in the serum of patients
116 with IBD and/or are genetically associated with disease risk (15). In addition, these serum
117 samples were also evaluated for the levels of 10 organic acids (OA), 21 amino acids (AA) and
118 88 acylcarnitines (AC); all key metabolite classes implicated in immune cell activity and/or
119 signaling. Moreover, we used an untargeted lipidomics approach that has previously been used
120 to identify host and microbial metabolic functions associated with CD pathogenesis (16). These
121 analyses enable two specific objectives: the first was to study the baseline samples to
122 determine whether any of these biological markers were associated with response to therapy,
123 and the second was to determine whether any changes in biomarker levels between weeks 0
124 and 14 were different between patients who experienced clinical response or remission
125 compared to non-responders.

126 **MATERIALS AND METHODS**

127 Subjects and Sample Collection

128 Characteristics of patients included in the current study are described in **Table S1**. Patients
129 were recruited at the Boston Massachusetts General Hospital (MGH) in 2014-2015 as part of a
130 prospective cohort previously described (12). All patients consented to have their data and
131 samples be part of the Prospective Registry in IBD Study at MGH (PRISM). CD and UC patients
132 starting vedolizumab therapy were considered for inclusion. Vedolizumab was administered
133 intravenously at weeks 0, 2, 6 and 14 at a dose of 300 mg. Patients who had completed the 3
134 infusion loading doses (weeks 0, 2 and 6) were included in the study. Disease was considered
135 clinically active when HBI score > 4 for CD and SCCAI score > 2 for UC. Study outcome was
136 achievement of either clinical response or remission at week 14. Response was defined as a
137 decrease from baseline HBI ≥ 3 for CD and a decrease from baseline SCCAI ≥ 3 for UC.
138 Remission was defined as HBI ≤ 4 and SCCAI ≤ 2 . Blood was collected in non-fasting subjects
139 at baseline and week 14 in SST tubes, ensuring rapid coagulation, which were processed within
140 24 hours of collection to collect the serum. Processed samples were stored at -80°C until the
141 various analyses were performed in 2016. A review of electronic medical records was
142 performed to obtain demographic and disease-related variables. Laboratory testing of serum
143 samples, as described below, was performed in 2016. All experiments were performed in
144 accordance with relevant guidelines and regulations. The Boston investigative team had access
145 to information that could identify individual participants during and after data collection, whereas
146 the Montreal team that performed the laboratory and statistical analyses only had access to
147 deidentified data and samples. The study was approved by the Institutional Review Board of
148 Partners Healthcare (protocol number 2004P001067/MGH) and the ethics committee of the
149 Montreal Heart Institute, known as the *Comité d'éthique de la recherche et du développement*
150 *des nouvelles technologies* (CERDNT; protocol number 2005-23; 05-813). Written informed
151 consent was obtained for all subjects.

152 Cytokine/chemokine measurements

153 The concentration of the 49 serum analytes were analyzed by quantitative cytokine assays
154 using Bio-Plex Pro™ human cytokine standard 27-Plex, 21-Plex and sCD40L Singleplex assays
155 (Bio-Rad Laboratories, California, USA) according to the pre-optimized protocol provided by the
156 manufacturer. Briefly, for each assay, the standard curve samples were plated in duplicate and
157 serum samples, some plated in duplicates, completed the 96-well plates. Samples were
158 processed on different plates and dates, using a balanced design. The serum was diluted 1:4 in

159 the buffer provided. Plates were labelled according to the manufacturer's specifications and
160 read by Bio-plex MAGPIX (Bio-Rad Laboratories, California, USA) at 525nm and 625nm and
161 identified/quantified using the CCD imager. The complete list of analytes tested can be found in
162 **Table S2**.

163 *QC Luminex data*

164 Obvious outlier samples were removed before processing the data. Fluorescence Intensity (FI)
165 distributions were normalized between plates using ComBat (library SVA, R 3.2.0) (17).
166 Standard curves were fitted using 5 parameters logistic curves on FI pooled from all plates. The
167 detection threshold was defined as the bottom value of the standard curve. Analytes with more
168 than 50% samples having FI below the detection limit were removed from the analysis after
169 verification that out-of-bound status was not associated with phenotype. Most remaining
170 analytes had more than 75% of samples within the range of reliable quantification (recovery of
171 standard concentration 70%-130%). One analyte, RANTES, had samples with FI above the
172 upper limit of detection. Data quality was evaluated based on correlation of replicates and
173 proportion of samples within range of quantification. To minimize impact of strong outliers,
174 outliers were replaced by a value equivalent to 1.5 IQR from the lower and upper quartiles. The
175 concentrations were then computed from the standard curve, with out-of-range values replaced
176 by the minimum (or maximum) quantified concentration.

177 *Metabolic Profiling*

178 Serum samples were obtained as frozen aliquots (-80°C) which had not been previously thawed
179 (15). Following recommended guidelines (18), stratified randomization of samples was
180 achieved according to potential confounding factors, namely age, sex, disease status and
181 treatment, to minimize batch-dependent bias. Metabolites were identified according to m/z and
182 retention time. For the targeted analyses, metabolites were quantified using internal standards
183 (see **Table S3**). MS quality controls (QCs) were performed by injecting "in-house" plasma pool
184 at the beginning, the end and every 12 runs. Samples were processed on different batches,
185 using a balanced design.

186 ***Targeted amino and organic acids analysis.*** Levels of 21 amino acids and 10 organic acids
187 were measured by gas chromatography-mass spectrometry (GC-MS) using methods previously
188 described (19) with some modifications. Serum (200 µl) was extracted with methanol and
189 hydroxylamine and a mixture of internal standards was added. Derivatization was performed
190 using N-methyl-N-tertbutyldimethylsilyltrifluoroacetamide. Samples were injected onto a GC-MS

191 and operated in electronic ionization mode with helium as reagent gas. Data were expressed as
192 concentrations.

193 **Targeted acylcarnitine profiling.** Extended profiling of 88 acylcarnitines (ACs) was performed
194 by liquid chromatography coupled to tandem mass spectrometry (LC-MS) as described (20).
195 Serum samples (100 μ l) were spiked with methanol containing internal standards and were
196 extracted consecutively with ethyl acetate, ether and methanol. The supernatants were
197 combined, concentrated and injected onto an HPLC (20). Data were monitored in positive
198 dynamic MRM mode (dMRM) for precursor ions of m/z 85 and processed by Mass Hunter QQQ
199 quantitative software. Semi-quantitative analysis was performed for carnitine and each
200 acylcarnitine by normalizing to the selected internal standard and data were expressed in signal
201 intensity ratios. In the text, we used the LIPID MAPS nomenclature (ref: [LIPID MAPS](#)). Isomers
202 of the same AC species, whose structure remains to be elucidated, are indicated using numbers
203 (e.g., AC#1/#2).

204 **QC of targeted metabolites.** Obvious outlier samples were removed before processing the
205 data. Missing values were presumed to be below detection range and thus, imputed to be 90%
206 of the minimum detected value. To minimize the impact of strong outliers, outliers were
207 investigated and replaced by a value equivalent to 2 IQR from the lower and upper quartiles.

208 **Untargeted lipidomic profiling:** Serum samples were analyzed using a previously validated
209 semi-quantitative untargeted lipidomic workflow for plasma and serum (21) on a high-resolution
210 LC-MS instruments (LC-quadrupole-time-of-flight (LC-QTOF 6530; Agilent Technologies Inc.).
211 MS data were acquired and QC measures performed as recently described(16). Raw MS data
212 were processed as previously described in detail using Mass Hunter Qualitative Analysis (version
213 B.06 or B.07; Agilent, Santa Clara, USA) for peak picking and in-house bioinformatic scripts
214 (available at MetaboICM/Metaborose (github.com) and MetaboICM/Data-processing: Script
215 (github.com)) that for RT alignment, filtering, missing data imputation and batch correction(21). A
216 maximal value of was set for the percentage of missing values or a given feature in any groups
217 at 20%, and for coefficient of interindividual variation <80%. We had previously determined that
218 median interindividual MS signal intensity variations in lipid features for the analysis of serum
219 samples from four non-fasting subjects prepared using our standard optimal collection protocol
220 was 33% and was manageable for successful application of our lipidomic workflow to serum
221 samples collected in patient cohorts (16). The resulting final dataset, thereafter, referred to as
222 features, defined by their m/z, RT and signal intensity. Lipid features of interest were then

223 annotated to unique lipids with their respective acyl chains, by MS/MS analysis, as previously
224 described (21).

225 ***Statistical associations analyses***

226 Statistical analyses were performed in R on \log_2 transformed data and thus represent fold
227 changes (FC). Single marker analyses for association to phenotype were performed using linear
228 regression including correction for gender, and with/without a correction for body mass index
229 (BMI, \log_2 transformed) to assess robustness. The targeted metabolites analyses were also
230 corrected for batch. The analyses were stratified for UC and CD. For lipidomics and proteomics,
231 evidence of association for IBD was obtained by combining UC and CD results using inverse
232 variance method. For targeted metabolites, the analysis was performed within all IBD. Disease
233 activity was tested on all baseline samples. The response status was tested in active disease
234 patients at baseline. From these patients with active disease at baseline, the subset with
235 available data at week 14 was used to evaluate association between response status and
236 markers ratio between week 14 and baseline. Multimarkers analyses were performed using
237 logistic regression. Loess regression (R function loess, span=0.6) was used to represent
238 association of BMI and specific markers.

239 For lipidomics, modules of correlated lipid features were created using the WGCNA (version,
240 v1.64–1) package in R, on \log_2 transformed data. The type of network used was “signed”, with
241 the “bicor” correlation function and softpower parameter set to 9. Minimal module size was set to
242 20 and hierarchical tree was cut at a height of 0.4 to determine clusters membership. We obtained
243 18 clusters, each represented by their respective first principal component.

244 Significant analytes were combined to evaluate their joint potential to predict response to therapy.
245 All significant analytes from targeted analyses (14), together with the first principal component
246 from lipidomics, were selected. Pairwise pearson correlation ($r < 0.6$) was used to reduce the
247 number of parameters, after prioritization of the most associated analytes. A logistic regression
248 analysis was performed, followed by stepwise bidirectional selection based on Aikake Information
249 Criterion (AIC) was performed to reduce the model. The final model was evaluated for area under
250 the roc curve (AUC). To be noted, no independent out of sample evaluation was performed, so it
251 is expected that the performance might be overestimated.

252

253 RESULTS

254 **Overall Study Design.** Ninety-two patients were recruited at the Boston Massachusetts
255 General Hospital (MGH) as part of a prospective cohort previously described (12). CD (n=42)
256 and UC (n=50) patients starting vedolizumab therapy were recruited. The demographic and
257 clinical phenotypes of these subjects are presented in **Table S1**. Serum samples were
258 collected just prior to initiation of treatment with vedolizumab and at week 14. Statistical
259 analyses were performed to examine two main objectives: (1) Identify which analytes had
260 baseline levels that were different in responders as compared with “non responders”; (2) Identify
261 analytes that changed significantly between baseline and after 14 weeks of treatment with
262 vedolizumab in responders versus non-responders. In the former analysis, the intention is to
263 identify biological pathways that favor treatment success in responders, and the latter analysis
264 is aimed at identifying biological pathways that are modified by therapy in responders. In both
265 analyses, “responder status” was defined as any patient having either clinical response or
266 remission at week 14 (see Methods). These two analyses were performed only in patients with
267 active disease at baseline. In addition, to place these analytes in context of disease activity, we
268 also compared baseline levels in patients with active disease and those with quiescent disease.
269 Finally, testing for association between each analyte and responder status was performed
270 separately in CD and UC, as treatment patterns and outcomes are often different between these
271 diseases. Nonetheless, given that multiple biological pathways are common to these two
272 diseases we also tested for association in the combined set of CD and UC cases to search for
273 potential commonalities. Although we highlight in the text below the phenotype (CD, UC, IBD)
274 where the association was the most significant, the full set of analyses are presented in the
275 accompanying tables.

276

277 **Targeted serum proteomics.** As a first step to identify biomarkers that are associated with
278 response to Vedolizumab treatment in IBD, we tested the serum samples from all 92 patients for
279 49 different analytes that represent products of genes within IBD loci, ligands for proteins
280 encoded by genes within IBD loci, as well as a broad selection of cytokines, chemokines and
281 growth factors known to play a role in a variety of immune functions (**Table S2**). Following
282 quality control analyses, 142 samples from 90 individuals (52 at week 14) were included and 35
283 of the analytes were deemed detectable with reliable quantification in patient sera (**Table S2**).
284 We first examined if baseline levels of these analytes were significantly associated ($P < 0.01$)
285 with response to treatment with vedolizumab. Indeed, we observed a nearly 2-fold greater

286 baseline serum levels ($P=7.0\times 10^{-3}$) of homodimeric platelet-derived growth factor subunit bb
287 (PDGF $\beta\beta$) in UC patients responding to treatment as compared to non-responders (**Table 1**;
288 **Fig. 1A**). Importantly, PDGF has been linked with angiogenesis in the context of chronic
289 inflammatory processes as well as in gut wound healing (22). While less significant ($P<0.05$),
290 there were four additional analytes (IL-1Ra, IL-4, IL-9, MIP-1b $P<0.05$) that were elevated at
291 baseline in responders with all but IL-4 being associated with M1 macrophages, whereas
292 CXCL12/SDF-1a, a chemokine associated with polarization of M2 macrophages (23), was 26%
293 lower (FC=0.74, $P=0.024$) in responders (**Fig. 1B**). Interestingly, none of the analytes tested in
294 baseline samples was significantly associated with disease activity (**Table 1, Table S2**). Steroid
295 use at baseline was not associated with response to therapy and had negligible impact on our
296 results (**Table S2**). Amongst responders, five CD and nine UC were in steroid-free remission
297 after 14 weeks of therapy. Interestingly, while lower baseline levels of CRP were found to be
298 suggestively associated to response in IBD ($P=0.077$), the associations reported between
299 proteomics and response are mostly independent from CRP (**Table S2**). In particular, in a
300 logistic regression model for response including both \log_2 (CRP) (OR=0.84, $P=0.31$), and
301 \log_2 (PDGF- $\beta\beta$) (OR=2.59, $P=0.049$), only PDGF- $\beta\beta$ remained significant. Similarly, in a logistic
302 regression model for response including both \log_2 (CRP) (OR=0.87, $P=0.40$), and \log_2 (SDF1-a)
303 (OR=0.19, $P=0.048$), only SDF1-a remained significant.

304 Next, we assessed whether there were any changes in analyte levels between baseline and
305 week 14 samples that were associated ($P<0.01$) with response to treatment with vedolizumab.
306 The two strongest differences were for CXCL9/MIG ($P=6.3\times 10^{-4}$), and for IL-10 ($P=9.5\times 10^{-3}$) in
307 patients with UC. Specifically, in responders CXCL9/MIG levels increased 61% (FC=1.61)
308 between baseline and week 14, whereas there was a 66% decrease (FC=0.44) in non-
309 responders (**Fig. 1C**). In contrast, serum levels of IL-10 decreased by 15% (FC=0.85) in
310 responders, with a 27% increase (FC=1.27) in non-responders (**Fig 1D**). While not as
311 statistically significant ($P<0.05$), we also observed an opposite effect of treatment on IL-1b, IL-
312 12p70, FGF and G-CSF in responders (decrease) vs non-responders (increase). These results
313 were found to be robust to steroid status changes between baseline and week 14. Changes in
314 CRP levels were not associated with response ($P=0.97$).

315

316

317 **Table 1. Top analytes associated with response to vedolizumab treatment**

Analyte	Pheno	Disease Activity: Baseline			Response Status: Baseline			Response Status: Week14/Week0		
		Effect	SE	P-Value	Effect	SE	P-Value	Effect	SE	P-Value
PDGF- $\beta\beta$	UC	-0.434	0.472	3.6E-1	0.943	0.328	7.0E-3	-0.120	0.303	7.0E-1
	CD	0.077	0.396	8.5E-1	-0.210	0.405	6.1E-1	-0.272	0.506	6.0E-1
	IBD	-0.134	0.303	6.6E-1	0.486	0.255	5.6E-2	-0.161	0.260	5.4E-1
SDF-1a	UC	0.067	0.265	8.0E-1	-0.433	0.183	2.4E-2	0.457	0.272	1.1E-1
	CD	0.064	0.231	7.8E-1	-0.166	0.250	5.1E-1	0.250	0.286	3.9E-1
	IBD	0.065	0.174	7.1E-1	-0.340	0.148	2.1E-2	0.359	0.197	6.8E-2
CXCL9/MIG	UC	0.118	0.742	8.7E-1	-0.930	0.458	5.1E-2	2.000	0.498	6.3E-4
	CD	0.366	0.579	5.3E-1	0.539	0.654	4.2E-1	-0.199	0.943	8.4E-1
	IBD	0.272	0.457	5.5E-1	-0.446	0.375	2.4E-1	1.521	0.441	5.6E-4
IL-10	UC	-0.189	0.350	5.9E-1	0.171	0.252	5.0E-1	-0.723	0.253	9.5E-3
	CD	0.266	0.308	3.9E-1	-0.059	0.359	8.7E-1	0.417	0.353	2.6E-1
	IBD	0.067	0.231	7.7E-1	0.095	0.206	6.4E-1	-0.335	0.206	1.0E-1
Lysine	UC	-0.494	0.150	2.1E-3	0.353	0.100	1.5E-3	-0.185	0.126	1.6E-1
	CD	-0.129	0.165	4.4E-1	0.116	0.188	5.5E-1	-0.174	0.265	5.3E-1
	IBD	-0.294	0.102	5.0E-3	0.239	0.090	1.0E-2	-0.084	0.113	4.6E-1
Alanine	UC	-0.127	0.170	4.6E-1	0.379	0.104	1.1E-3	-0.219	0.160	1.9E-1
	CD	-0.189	0.158	2.4E-1	0.027	0.174	8.8E-1	0.353	0.281	2.4E-1
	IBD	-0.158	0.103	1.3E-1	0.222	0.086	1.3E-2	0.012	0.142	9.3E-1
Phenylalanine	UC	-0.344	0.186	7.2E-2	0.457	0.122	8.8E-4	-0.301	0.160	8.1E-2
	CD	-0.151	0.149	3.2E-1	0.112	0.168	5.1E-1	-0.315	0.324	3.6E-1
	IBD	-0.201	0.110	7.1E-2	0.251	0.093	9.2E-3	-0.160	0.135	2.5E-1
Citrate	UC	0.044	0.178	8.1E-1	0.036	0.143	8.0E-1	-0.018	0.195	9.3E-1
	CD	-0.261	0.144	7.8E-2	-0.257	0.158	1.3E-1	0.487	0.144	8.0E-3
	IBD	-0.109	0.105	3.0E-1	-0.051	0.102	6.2E-1	0.066	0.138	6.4E-1
Lactate	UC	0.166	0.215	4.4E-1	0.535	0.149	1.3E-3	-0.340	0.204	1.2E-1
	CD	-0.388	0.174	3.3E-2	-0.088	0.191	6.5E-1	-0.121	0.274	6.7E-1
	IBD	-0.176	0.127	1.7E-1	0.287	0.115	1.6E-2	-0.248	0.154	1.2E-1
AC 10:1 #2	UC	0.353	0.378	3.6E-1	0.895	0.317	8.8E-3	0.091	0.207	6.7E-1
	CD	0.639	0.312	4.9E-2	-0.007	0.387	9.9E-1	0.312	0.513	5.6E-1
	IBD	0.500	0.220	2.6E-2	0.447	0.225	5.2E-2	0.095	0.190	6.2E-1
AC 3:0	UC	-0.468	0.252	7.0E-2	0.505	0.154	2.9E-3	-0.110	0.203	6.0E-1
	CD	-0.165	0.229	4.8E-1	0.542	0.223	2.8E-2	0.294	0.346	4.2E-1
	IBD	-0.349	0.159	3.1E-2	0.506	0.126	2.0E-4	0.079	0.158	6.2E-1
AC 4:0 #1	UC	-1.166	0.490	2.2E-2	0.804	0.369	3.8E-2	0.071	0.363	8.5E-1
	CD	-0.283	0.360	4.4E-1	0.820	0.426	7.3E-2	-0.193	0.529	7.2E-1
	IBD	-0.679	0.279	1.7E-2	0.761	0.245	3.1E-3	0.009	0.246	9.7E-1
AC 5:0 #2	UC	-0.439	0.204	3.8E-2	0.279	0.135	4.8E-2	0.318	0.259	2.4E-1
	CD	-0.286	0.223	2.1E-1	0.472	0.210	4.0E-2	-0.049	0.304	8.8E-1
	IBD	-0.332	0.148	2.8E-02	0.335	0.118	6.3E-3	0.112	0.178	5.3E-1
AC 5:0 #3	UC	-0.752	0.359	4.3E-2	0.709	0.270	1.4E-2	0.050	0.361	8.9E-1
	CD	-0.147	0.271	5.9E-1	0.416	0.347	2.5E-1	0.080	0.534	8.8E-1
	IBD	-0.441	0.214	4.3E-2	0.548	0.202	9.0E-3	0.117	0.256	6.5E-1
Lipidomics PC1 (scaled)	UC	0.199	0.417	6.4E-1	0.553	0.315	8.9E-2	-0.318	0.424	4.6E-1
	CD	-0.359	0.317	2.6E-1	0.453	0.276	1.2E-1	0.355	0.417	4.1E-1
	IBD	-0.114	0.259	6.6E-1	0.496	0.208	1.7E-2	0.024	0.297	9.4E-1
Lipidomics Blue module	UC	0.044	0.031	1.7E-1	0.029	0.024	2.4E-1	-0.034	0.029	2.5E-1
	CD	-0.023	0.030	4.4E-1	0.076	0.027	1.1E-2	-0.004	0.033	9.1E-1
	IBD	0.006	0.022	7.7E-1	0.050	0.018	5.8E-3	-0.021	0.022	3.4E-1

318 Effect is $\log_2(\text{Fold-Change})$ except for lipidomics (means difference). Values in bold are ($p < 0.05$).

319 See **Table S2 to S5**.

320 ***Targeted serum metabolomics – organic acids, amino acids, and acylcarnitines.***

321 Serum levels of 10 organic acids and 21 amino acids were measured by isotope dilution gas
322 chromatography coupled with mass spectrometry (GC-MS). Regarding organic acids, we
323 observed changes in common proxies of cell energy metabolism, namely in baseline samples,
324 higher levels of lactate, reflecting cytosolic anaerobic glycolysis, (FC=1.45, $P=1.3\times 10^{-3}$) that
325 were associated with response to treatment in UC patients (**Fig. 2**) and between baseline and
326 week 14 samples, a larger increase (FC=1.44, $P=8.0\times 10^{-3}$) in levels of citrate, the first
327 intermediate of mitochondrial Krebs cycle, in patients with CD responding to treatment,
328 compared to non-responders. (**Fig. 2**).

329 As for amino acids, we observed that the baseline levels of multiple amino acids were
330 significantly associated with therapeutic response (**Table 1; Table S3**). In particular, essential
331 amino acids, namely the branched chain amino acid (BCAA) leucine ($P=9.3\times 10^{-3}$), the sulfur-
332 containing methionine ($P=1.3\times 10^{-3}$), and phenylalanine ($P=9.2\times 10^{-3}$), were significantly higher at
333 baseline in IBD patients that responded to therapy as compared to non-responders. This was
334 also observed in the UC subgroup, although many more amino acids were elevated in baseline
335 samples of responders, such as lysine and alanine, the latter concurring with our findings of
336 higher lactate levels ($P<2\times 10^{-3}$) (**Fig. 2; Table S3**). Interestingly, when comparing baseline
337 samples from patients with active disease to those with quiescent disease, we observed some
338 overlap with the previous analysis and as well as a distinct set of metabolites associated with
339 active disease. For example, lower serum levels of asparagine, glycine, histidine, and lysine
340 were associated with active disease in UC patients (**Table S3**). We did not observe any
341 significant changes in amino acid levels between baseline samples and those taken at 14
342 weeks post initiation of therapy.

343 Extended profiling of 88 ACs was performed by liquid chromatography coupled to tandem mass
344 spectrometry. Acylcarnitines are recognized proxies of perturbations in fatty acid and BCAA
345 oxidation, but can also exert biological activities, including to activate pro-inflammatory
346 pathways in macrophages (24). In patients with IBD, both UC and CD, we found that elevated
347 levels in baseline samples of four acylcarnitines containing short odd- and even chains (AC 3:0,
348 AC 4:0 #1, AC 5:0 #2, AC 5:0 #3) were associated ($P<0.01$) with response to therapy (**Fig. 2**).
349 Lower levels of these same acylcarnitines were modestly associated ($P<0.05$) with active
350 disease suggesting that successful treatment normalized the levels of these metabolites. In
351 patients with UC, response was also associated with elevated levels of AC 10:1 #2 in baseline
352 samples. While there is a difference in specific identities between IBD and UC analyses, it

353 should be noted that all are short-to-medium chain acylcarnitines. We did not detect any
354 changes in acylcarnitine levels between baseline and week 14 samples that were associated
355 with response in patients with CD, UC, or IBD.

356 In addition to analyzing individual metabolites, we also considered 11 ratios and groupings of
357 metabolites (**Table S3**). For baseline values, grouping all odd short chains AC (AC 3:0, AC 5:1,
358 AC 5:0 #1, AC 5:0 #2, AC 5:0 #3), associated with BCAA metabolism, was associated to
359 response in IBD ($P=8.4\times 10^{-4}$, $FC=1.36$), UC ($P=4.6\times 10^{-3}$, $FC=1.38$) and suggestively in CD
360 ($P=0.06$, $FC=1.37$). We also found evidence of association for BCAA (Leucine, Isoleucine,
361 Valine) with response to therapy in UC ($P=3.5\times 10^{-3}$, $FC=1.33$) and IBD ($P=0.011$, $FC=1.21$).

362

363 **Untargeted serum lipidomics**

364 We conducted LC-MS-based lipidomic profiling on these same samples. Raw data consisting of
365 1364 MS signals were processed as previously described (16, 21) for RT alignment, filters of
366 presence, normalization of signal intensities, and imputation of missing values. Following this
367 data processing, the final dataset retained 1111 lipid features, defined by their m/z, RT and
368 signal intensity. In IBD, we identified 63 lipid features that were significantly ($P<0.05$) elevated
369 and 44 that were lower in baseline serum samples from responders as compared to non-
370 responders (**Fig 3A**, Volcano plot). To account for multiple testing and because high
371 dimensional lipidomic data is known to have a correlation structure, we used WGCNA and
372 defined 18 clusters of correlated lipid features (illustrated as the colors in **Fig 3A**), each
373 represented by their first principal component. We identified one cluster (denoted blue),
374 associated with response to therapy in IBD ($P=5.8\times 10^{-3}$) in baseline samples (**Table S4**). This
375 module was also found to be associated with diagnosis (higher in CD vs UC, $P=9.1\times 10^{-3}$). Next,
376 we performed principal components analysis with all 1111 lipid features on baseline samples
377 and observed that the first principal component (PC1) was also associated with response status
378 in IBD ($P=0.017$) (**Fig. 3B, Table 1, Table S4**). Notably, the first principal component (PC1)
379 was also significantly associated with body mass index (BMI) ($P=5.1\times 10^{-5}$), while BMI was not
380 found to be significantly associated to response status ($P=0.68$). Conditional analyses
381 confirmed that the PC1 is associated to both BMI and response status, with a possible
382 interaction between them. Overweight patients (BMI >25 kg/m²) who responded to therapy had
383 higher values on PC1 at baseline than non-responders of similar BMI (**Fig. 3C**). When
384 examining the loadings for the individual metabolites for PC1, we observed a predominant
385 impact of lipid features from the same module (blue module) (**Fig 3D**), to which PC1 was also

386 **Table 2. Top lipid features**

Compound Name	Lipid abbreviation	Pheno	Response Status: Baseline			BMI : Baseline			Correlation with PC1		
			log2(FC)	SE	P-Value	log2(FC)	SE	P-Value	Pearson r	P-value	Loadings
POS:740.5911@41.37	TG42:2	UC	1.41	0.56	1.6E-02	2.03	1.24	1.1E-01	0.64	6.9E-10	0.091
		CD	1.87	0.72	1.7E-02	0.60	1.13	6.0E-01			
		IBD	1.59	0.44	3.1E-04	1.25	0.83	1.3E-01			
POS:711.6357@43.30	TG40:0	UC	0.96	0.45	4.1E-02	2.85	1.00	7.8E-03	0.61	5.8E-09	0.076
		CD	1.50	0.69	4.1E-02	1.73	1.08	1.2E-01			
		IBD	1.12	0.38	2.9E-03	2.34	0.74	1.5E-03			
POS:737.6516@43.56	TG42:1	UC	1.27	0.57	3.4E-02	3.85	1.27	4.9E-03	0.65	5.1E-10	0.110
		CD	2.57	0.91	1.1E-02	1.47	1.43	3.2E-01			
		IBD	1.64	0.49	7.5E-04	2.81	0.95	3.2E-03			
POS:763.6672@44.01	TG44:2	UC	1.14	0.53	3.9E-02	3.60	1.17	4.4E-03	0.68	2.1E-11	0.099
		CD	1.67	0.66	1.9E-02	1.42	1.03	1.8E-01			
		IBD	1.35	0.41	1.1E-03	2.37	0.77	2.2E-03			
POS:739.6673@46.76	TG42:0	UC	0.97	0.49	5.5E-02	2.94	1.08	1.1E-02	0.64	8.9E-10	0.089
		CD	1.75	0.75	2.9E-02	1.95	1.17	1.1E-01			
		IBD	1.20	0.41	3.2E-03	2.49	0.79	1.7E-03			
POS:823.7606@51.47	TG44:0	UC	1.94	0.73	1.2E-02	4.66	1.61	7.0E-03	0.66	2.3E-10	0.129
		CD	1.61	1.17	1.8E-01	1.40	1.83	4.5E-01			
		IBD	1.85	0.62	2.7E-03	3.23	1.21	7.5E-03			

387 Loadings: loadings (rotation matrix) attributed to each lipid in the PCA for PC1.

388 See **Table S5** for further details.

389

390 found to be correlated ($r=0.77$, $P=8 \times 10^{-16}$). Investigating on the nature of this signal, we
 391 identified at least six metabolites that were significantly correlated with PC1 ($r>0.6$, $P<5 \times 10^{-8}$),
 392 contributed a large amount of the component (loading $> 7.5\%$) and that were significantly
 393 associated with response to therapy ($P < 0.01$, $q < 0.20$) (**Table S5** and **Fig. 3D**). These were all
 394 triglycerides (TG) and were elevated in baseline samples of responders in comparison with NR:
 395 TG 40:0 ($P=2.9 \times 10^{-3}$); TG 42:0 ($P=3.2 \times 10^{-3}$); TG 42:1 ($P=7.5 \times 10^{-4}$); TG 42:2 ($P=3.1 \times 10^{-4}$); TG
 396 44:2 ($P=1.0 \times 10^{-3}$); TG 48:0 ($P=2.7 \times 10^{-3}$). Triglycerides are formed from glycerol and three fatty
 397 acids (FA). We thus performed MS/MS analyses to identify the specific fatty acids that
 398 constitute these TGs and all contained medium chain FA (MCFA), with 10 to 12 carbons in
 399 length, and/or long chain fatty acids (LCFA), with 14, 16, or 18 carbons in length; primarily
 400 saturated or monounsaturated (**Table 2, Table S5**). Interestingly, almost all contained myristic
 401 acid (C14). In terms of changes of individual lipid metabolites between baseline and week 14
 402 samples in patients with CD, the PC1 and blue module described above were not found to be
 403 significantly impacted by therapy ($P=0.89$, $P=0.18$) and there was no significant difference
 404 between responders and non-responders. It is noteworthy that PC1 was not found to be
 405 associated with CRP levels ($r=-0.02$, $P=0.87$), suggesting that these are capturing different
 406 biological pathways.

407 In summary, the lipidomic PC1 and PC1-correlated analytes at baseline are associated to
408 response to therapy and BMI, while BMI alone is not informative to predict response to therapy.
409 There is also no evidence of an effect of therapy on these markers after 14 weeks.

410

411 **Correlation between biomarker types and logistic regression-based models.**

412 As it is likely that different biomarker types can reflect different aspects of the same pathway, we
413 tested for correlation between the biomarkers reported above. Specifically, we looked for
414 correlation between the lipidomic and proteomic data and found that the PC1 described above
415 was found to be significantly correlated with CXCL1/GRO α ($r=-0.30$, $P=8.6\times 10^{-3}$), SDF-1a ($r=-$
416 0.31 , $P=7.3\times 10^{-3}$) and IL-13 ($r=0.32$, $P=4.7\times 10^{-3}$). As described above, lower baseline levels of
417 SDF-1a were associated with response in IBD patients, while we found CXCL1/GRO α to be
418 suggestively associated ($P=0.054$). A logistic regression model including both lipidomic PC1
419 and SDF-1a explained more variation in response ($P=8.8\times 10^{-3}$) than model including only the
420 covariates (diagnosis and BMI). There is suggestive evidence that including both explains more
421 variation than either one of them, pointing to a possible common signal that would be
422 imperfectly captured by each parameter alone. In these models we obtained a similar, but
423 slightly more significant association ($P=3.3\times 10^{-3}$), when using the blue module instead of whole
424 data PC1, suggesting that the observed association is primarily driven by lipids within this
425 module.

426 The PC1 was also significantly correlated to many targeted metabolites, in particular to AC 3:0
427 (Pearson $r=0.56$, $P=2.1\times 10^{-7}$), AC 4:0 (Pearson $r=0.53$, $P=1.4\times 10^{-6}$) and the grouping of odd
428 short chain AC (Pearson $r=0.53$, $P=8.1\times 10^{-7}$) that we found to be associated to response to
429 therapy in IBD (**Table S3**). Given their correlation to PC1, we then tested for association to BMI,
430 which is what was observed ($P<1E-3$). Conditional regression identified that most of the signal
431 is captured by AC 3:0, which remains associated with response to therapy when we condition
432 on PC1, the other metabolites or SDF-1a. Investigating further on this, we identified for AC 3:0 a
433 similar trend than PC1 for BMI and response to therapy, with overweight patients (BMI >25
434 kg/m²) who responded to therapy having higher values of AC 3:0 at baseline (**Fig S1**),
435 suggesting that AC 3:0, PC1 and SDF-1a might be capturing a common biological state at
436 baseline.

437 We then investigated the ability to predict response to therapy, using the most associated
438 markers. Using AC 3:0 alone in the model for IBD gave an AUC=0.75. We then obtained a

439 logistic regression model for predicting response based on PC1, AC 3:0, lactate, phenylalanine,
440 AC 10:1 #2, PDGF- $\beta\beta$, IL-1Ra, and SDF-1a. These were selected from all the associated
441 analytes ($p < 0.05$), after keeping only a subset with pairwise Pearson correlation < 0.6 . The
442 model was then reduced based on AIC (see Methods). The final model for IBD included AC 3:0,
443 IL-1Ra and UC/CD phenotype. The AUC obtained was 0.78. The final model for UC included
444 PDGF- $\beta\beta$, lactate and AC 10:1 #2. The AUC obtained was 0.89. It is to be noted that these
445 models are exploratory, as this process is subject to overestimation of performance

446

447

448 **DISCUSSION**

449 The analyses of patient serum samples performed in this proof-of-concept study presented
450 herein has identified candidate biomarkers associated with response to treatment with
451 vedolizumab in patients with IBD. While these biomarkers must be validated in independent
452 cohorts by other groups, these results support the notion that there are biological differences
453 between responders and non-responders. While most of the strongest associations were
454 observed in the UC subgroup, future studies will be required to determine whether this was
455 simply due to sample size or biological differences. Given the known functions of the analytes
456 and metabolites that were found associated with response to treatment in this cohort, we were
457 interested in examining how these findings could be placed in the context of the known
458 mechanism of action for vedolizumab. Specifically, it is believed that it interferes with leukocyte
459 trafficking to the intestines (25).

460 The opposite changes in serum expression of CXCL9/MIG and IL-10 between baseline and
461 week 14 samples is consistent with the former being pro-inflammatory chemokine, produced by
462 macrophages, endothelial cells and fibroblasts (26), and the latter an anti-inflammatory cytokine,
463 primarily produced by T helper cells, macrophages and dendritic cells (27, 28). One possible
464 explanation is that successful treatment prevents CXCL9/MIG-producing pro-inflammatory cells
465 from trafficking to the intestines, while not preventing the IL-10-producing cells from doing so.
466 While the treatment with vedolizumab is likely to impact the trafficking of multiple different cell
467 types expressing $\alpha 4\beta 7$ integrin, including monocytes, macrophages, as well as B, T, and NK
468 cells (29, 30), it is important to note that M1 macrophages are associated with expression of
469 CXCL9/MIG and M2 macrophages with IL-10. Intriguingly, responders also had lower baseline
470 levels of CXCL12/SDF-1a, a chemokine associated with M2 macrophages (23). In UC, we also

471 found that elevated baseline serum levels of PDGF β was associated with response to
472 vedolizumab. It is believed that elevated levels of platelet derived growth factor (PDGF) may
473 reflect active tissue remodeling given that it is a potent mitogen for cells of mesenchymal origin
474 and a likely mediator of epithelial-mesenchyme transition (31).

475 Interestingly, the results from the targeted and untargeted metabolomics are also consistent
476 with retention of M1 macrophages in the circulation, which contribute to type 1 immune
477 responses, where IFN- γ is the prototypical cytokine. Specifically, it is known that in pro-
478 inflammatory M1 macrophages preferentially use the glycolytic pathway, whereas the anti-
479 inflammatory M2 use fatty acid oxidation (FAO) and OXPHOS pathways for energy production
480 (32, 33). Elevated levels of lactate, alanine and PC1 containing TG species in baseline samples
481 are consistent with these metabolic differences (24, 34) . Furthermore, it has also been reported
482 that macrophages activated with IFN- γ increase glucose uptake and lactate release, increases
483 TG levels, and induces lipid droplet (LD) accumulation (35, 36). This LD accumulation is
484 dependent on exogenous fatty acids and is characteristic of M1 macrophages (35, 36).
485 Interestingly, the MS/MS analyses identified that most of these TGs had at least one myristic
486 acid (C14) chain. Myristic acid is a side chain to Phorbol Myristate Acetate (PMA), which is a
487 well know immune cell activator. Myristic acid alone can activate immune cells, and act as
488 metabolic checkpoint for macrophage responses by promoting N-myristoylation (37-39).

489 While the hypothesis that we propose to explain our observations remains speculative, findings
490 by Zeissig and colleagues, however, are consistent with our hypothesis as they observed that
491 transcriptomic profiles that reflected lower M1 and higher M2 in the colonic tissue in response to
492 Vedolizumab (11). This is also consistent with prior observations that an imbalance in M1/M2
493 promotes inflammation, with M1 macrophages dominating disease development, destructive
494 aspects of inflammation, and disease severity in inflammatory diseases (40-42). Nonetheless,
495 we can't formally discount a metabolic shift from M2 to M1 macrophages within the circulation,
496 or that the patterns of serum biomarkers observed are due to the retention of other cell types. In
497 addition, this hypothesis does not exclude other mechanisms for differential response, for
498 example, a recent study reported an attenuation of the gut associated lymphoid tissue in
499 patients treated with Vedolizumab (43).

500 It should be acknowledged that these findings are based on a single cohort and thus need to be
501 validated in independent cohorts, ideally within the context of prospective studies comparing
502 multiple different advanced therapies to determine whether these observations are specific to
503 vedolizumab treatment or are applicable to other molecularly targeted therapies. In addition,

504 future studies would also include nutritional status of patients, measures of other clinical
505 biomarkers, and potentially other measures of treatment response. In terms of CRP levels, we
506 found some suggestive association between response and CRP at baseline, but none for CRP
507 changes between baseline and week 14. To place these results in context, a review of 16
508 recent studies of response to Vedolizumab, association of CRP with response to vedolizumab
509 was assessed in 7 of 16 studies; no association was detected in 4 studies, higher levels in
510 responders in 2 studies, lower levels in responders in one study (11, 44-58). While the lack of
511 endoscopy data in the current study can be viewed as a weakness of the current study, one
512 could argue that clinical response/remission is more relevant outcome at this early timepoint of
513 14 weeks, and endoscopic changes more relevant to later time points, given a recent study that
514 found that as ~12% of patients achieve endoscopic remission at **week 26**, and ~18% at **week**
515 **52** (59)). Finally, although these limitations highlight that the results of the current study will not
516 immediately be translated into better treatment selection process, we believe that this study
517 represents a proof-of-concept that a multi'omic approach can help to uncover the biological
518 heterogeneity that is related to differential treatment response.

519 **ACKNOWLEDGEMENTS**

520 The members of the iGenoMed Consortium at the time of this study were (in alphabetical order):
521 Alain Bitton^{1*}, Gabrielle Boucher², Guy Charron², Christine Des Rosiers^{2,3*}, Anik Forest², Philippe
522 Goyette², Sabine Ivison⁴, Lawrence Joseph^{5*}, Rita Kohen¹, Jean Lachaine^{6*}, Sylvie Lesage^{3,7*},
523 Megan Levings^{4*}, John D. Rioux^{2,3*}, Julie Thompson Legault², Luc Vachon⁸, Sophie Veilleux^{9*},
524 Brian White-Guay^{3*}. **Affiliations:** ¹McGill University Health Centre, Montreal, Quebec; ²Montreal
525 Heart Institute Research Center, Montreal, Quebec; ³Université de Montréal, Faculté de
526 Médecine, Montreal; ⁴University of British Columbia, Vancouver; ⁵McGill University, Faculty of
527 Medicine, Department of Epidemiology, Biostatistics and Occupational Health; ⁶Université de
528 Montréal, Faculté de Pharmacie; ⁷Maisonneuve-Rosemont Hospital, Research Center, Montreal;
529 ⁸LV Consulting, Montreal; ⁹Université de Laval, Québec. *Principal Investigators on grant # GPH-
530 129341 with JDR as Leader and AB as co-Leader.

531

532 **AUTHOR CONTRIBUTIONS:**

533 John D. Rioux (Conceptualization: Lead; Validation: Lead; Resources: Equal; Writing – original
534 draft: Lead; Supervision: Lead; Project administration: Lead; Funding acquisition: Lead; Writing
535 – review & editing: Lead)

536 Gabrielle Boucher (Formal analysis: Equal; Data curation: Equal; Writing – original draft: Equal;
537 Writing – review & editing: Equal; Visualization: Equal)

538 Anik Forest (Formal analysis: Equal; Investigation: Equal; Data curation: Equal; Writing – review
539 & editing: Equal; Visualization: Equal)

540 Bertrand Bouchard (Investigation: Equal)

541 Lise Coderre (Formal analysis: Supporting)

542 Caroline Daneault (Investigation: Equal)

543 Isabelle Robillard Frayne (Investigation: Equal)

544 Julie Thompson Legault (Writing – original draft: Equal; Writing – review & editing: Equal)

545 Alain Bitton (Funding acquisition: Lead)

546 Ashwin Ananthakrishnan (Resources: Equal)

547 Sylvie Lesage (Conceptualization: Supporting; Resources: Supporting)

548 Ramnik J. Xavier (Resources: Equal)

549 Christine Des Rosiers (Conceptualization: Lead; Validation: Lead; Resources: Equal,
550 Supervision: Lead, Project administration: Equal; Funding acquisition: Equal; Writing – review &
551 editing: Equal)

552

553 **ADDITIONAL INFORMATION**

554

555 **DATA AVAILABILTY STATEMENT:**

556 Individual-level raw data will be made available via the NIDDK IBD Genetics Consortium

557 (<https://www.ibdgc.org/research/resources>).

558

559 **COMPETING INTERESTS STATEMENT**

560 Authors have no potential conflicts (financial, professional, or personal) or competing interests

561 relevant to the manuscript.

562

563 **GRANT SUPPORT**

564 The authors would like to acknowledge the financial support of Génome Québec, Genome

565 Canada, the Government of Canada, and the Ministère de l'enseignement supérieur, de la

566 recherche, de la science et de la technologie du Québec, the Canadian Institutes of Health

567 Research (with contributions from the Institute of Infection and Immunity, the Institute of Genetics,

568 and the Institute of Nutrition, Metabolism and Diabetes), Genome BC, and Crohn's Colitis Canada

569 via the 2012 Large-Scale Applied Research Project competition (grant # GPH-129341). This work

570 was also supported by a grant from the National Institutes of Diabetes, Digestive and Kidney

571 Diseases (DK062432 to JDR). JDR holds a Canada Research Chair (#230625 to JDR). This

572 project also benefited from infrastructure supported by the Canada Foundation for Innovation

573 (grant numbers 202695, 218944, 20415 to JDR and 36283 to CDR). The sponsors had no role in

574 the study design and in the collection, analysis, and interpretation of data.

575

576 **ABBREVIATIONS**

577 AC: Acylcarnitines

578 AA: Amino acids

579 BMI: body mass index

580 BCAA: branched chain amino acid

581 FC: fold change

582 FI: fluorescence intensity

583 GC-MS: gas chromatography coupled with mass spectrometry

584 IQR: interquartile range

585 LC-MS: liquid chromatography coupled to tandem mass spectrometry

586 LCFA: long chain fatty acids

587 MCFA: medium chain FA

588 m/z: mass-to-charge ratios

589 OA: organic acids

590 PCA: principal components analysis

591 PC1: principal component 1 from lipidomics

592 QC: quality controls
593 RT: retention time
594 TG: triglycerides
595 WGCNA: Weighted Correlation Network Analysis

596
597
598

599 REFERENCES

600

- 601 1. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical
602 Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol.* 2018;113(4):481-517.
- 603 2. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline:
604 Ulcerative Colitis in Adults. *Am J Gastroenterol.* 2019;114(3):384-413.
- 605 3. Barber GE, Yajnik V, Khalili H, Giallourakis C, Garber J, Xavier R, et al. Genetic Markers
606 Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's
607 Disease. *Am J Gastroenterol.* 2016;111(12):1816-22.
- 608 4. Oliver J, Plant D, Webster AP, Barton A. Genetic and genomic markers of anti-TNF
609 treatment response in rheumatoid arthritis. *Biomark Med.* 2015;9(6):499-512.
- 610 5. Baird AC, Mallon D, Radford-Smith G, Boyer J, Piche T, Prescott SL, et al. Dysregulation
611 of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy. *World
612 J Gastroenterol.* 2016;22(41):9104-16.
- 613 6. Fuchs F, Schillinger D, Atreya R, Hirschmann S, Fischer S, Neufert C, et al. Clinical
614 Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin
615 Expression Profiles. *Front Immunol.* 2017;8:764.
- 616 7. Van den Brande JM, Koehler TC, Zelinkova Z, Bennink RJ, te Velde AA, ten Cate FJ, et
617 al. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis
618 in patients with Crohn's disease. *Gut.* 2007;56(4):509-17.
- 619 8. Arijis I, Li K, Toedter G, Quintens R, Van Lommel L, Van Steen K, et al. Mucosal gene
620 signatures to predict response to infliximab in patients with ulcerative colitis. *Gut.*
621 2009;58(12):1612-9.
- 622 9. Tew GW, Hackney JA, Gibbons D, Lamb CA, Luca D, Egen JG, et al. Association Between
623 Response to Etrolizumab and Expression of Integrin alphaE and Granzyme A in Colon Biopsies
624 of Patients With Ulcerative Colitis. *Gastroenterology.* 2016;150(2):477-87 e9.
- 625 10. Sly LM, McKay DM. Macrophage immunotherapy: overcoming impediments to realize
626 promise. *Trends Immunol.* 2022;43(12):959-68.
- 627 11. Zeissig S, Rosati E, Dowds CM, Aden K, Bethge J, Schulte B, et al. Vedolizumab is
628 associated with changes in innate rather than adaptive immunity in patients with inflammatory
629 bowel disease. *Gut.* 2019;68(1):25-39.
- 630 12. Shelton E, Allegretti JR, Stevens B, Lucci M, Khalili H, Nguyen DD, et al. Efficacy of
631 Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort. *Inflamm
632 Bowel Dis.* 2015;21(12):2879-85.
- 633 13. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. *Lancet.*
634 1980;1(8167):514.
- 635 14. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index.
636 *Gut.* 1998;43(1):29-32.
- 637 15. Boucher G, Paradis A, Chabot-Roy G, Coderre L, Hillhouse EE, Bitton A, et al. Serum
638 Analyte Profiles Associated With Crohn's Disease and Disease Location. *Inflamm Bowel Dis.*
639 2021.
- 640 16. Ferru-Clement R, Boucher G, Forest A, Bouchard B, Bitton A, Lesage S, et al. Serum
641 Lipidomic Screen Identifies Key Metabolites, Pathways, and Disease Classifiers in Crohn's
642 Disease. *Inflamm Bowel Dis.* 2023;29(7):1024-37.

- 643 17. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data
644 using empirical Bayes methods. *Biostatistics*. 2007;8(1):118-27.
- 645 18. Burla B, Arita M, Arita M, Bendt AK, Cazenave-Gassiot A, Dennis EA, et al. MS-based
646 lipidomics of human blood plasma: a community-initiated position paper to develop accepted
647 guidelines. *J Lipid Res*. 2018;59(10):2001-17.
- 648 19. Thompson Legault J, Strittmatter L, Tardif J, Sharma R, Tremblay-Vaillancourt V, Aubut
649 C, et al. A Metabolic Signature of Mitochondrial Dysfunction Revealed through a Monogenic Form
650 of Leigh Syndrome. *Cell Rep*. 2015;13(5):981-9.
- 651 20. Ruiz M, Labarthe F, Fortier A, Bouchard B, Thompson Legault J, Bolduc V, et al.
652 Circulating Acylcarnitine Profile in Human Heart Failure: A Surrogate of Fatty Acid Metabolic
653 Dysregulation in Mitochondria and Beyond. *Am J Physiol Heart Circ Physiol*. 2017:ajpheart 00820
654 2016.
- 655 21. Forest A, Ruiz M, Bouchard B, Boucher G, Gingras O, Daneault C, et al. Comprehensive
656 and Reproducible Untargeted Lipidomic Workflow Using LC-QTOF Validated for Human Plasma
657 Analysis. *J Proteome Res*. 2018;17(11):3657-70.
- 658 22. Alkim C, Alkim H, Koksal AR, Boga S, Sen I. Angiogenesis in Inflammatory Bowel Disease.
659 *Int J Inflamm*. 2015;2015:970890.
- 660 23. Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage plasticity and
661 polarization in tissue repair and remodelling. *J Pathol*. 2013;229(2):176-85.
- 662 24. Rutkowsky JM, Knotts TA, Ono-Moore KD, McCoin CS, Huang S, Schneider D, et al.
663 Acylcarnitines activate proinflammatory signaling pathways. *Am J Physiol Endocrinol Metab*.
664 2014;306(12):E1378-87.
- 665 25. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al.
666 Vedolizumab as induction and maintenance therapy for ulcerative colitis. *N Engl J Med*.
667 2013;369(8):699-710.
- 668 26. Ohmori Y, Schreiber RD, Hamilton TA. Synergy between interferon-gamma and tumor
669 necrosis factor-alpha in transcriptional activation is mediated by cooperation between signal
670 transducer and activator of transcription 1 and nuclear factor kappaB. *J Biol Chem*.
671 1997;272(23):14899-907.
- 672 27. Iyer SS, Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and
673 autoimmune disease. *Crit Rev Immunol*. 2012;32(1):23-63.
- 674 28. Italiani P, Boraschi D. From Monocytes to M1/M2 Macrophages: Phenotypical vs.
675 Functional Differentiation. *Front Immunol*. 2014;5:514.
- 676 29. Tyler CJ, Guzman M, Lundborg LR, Yeasmin S, Zgajnar N, Jedlicka P, et al. Antibody
677 secreting cells are critically dependent on integrin alpha4beta7/MAdCAM-1 for intestinal
678 recruitment and control of the microbiota during chronic colitis. *Mucosal Immunol*. 2022;15(1):109-
679 19.
- 680 30. Schleier L, Wiendl M, Heidbreder K, Binder MT, Atreya R, Rath T, et al. Non-classical
681 monocyte homing to the gut via alpha4beta7 integrin mediates macrophage-dependent intestinal
682 wound healing. *Gut*. 2020;69(2):252-63.
- 683 31. Wu Q, Hou X, Xia J, Qian X, Miele L, Sarkar FH, et al. Emerging roles of PDGF-D in EMT
684 progression during tumorigenesis. *Cancer Treat Rev*. 2013;39(6):640-6.
- 685 32. Huang SC, Everts B, Ivanova Y, O'Sullivan D, Nascimento M, Smith AM, et al. Cell-
686 intrinsic lysosomal lipolysis is essential for alternative activation of macrophages. *Nat Immunol*.
687 2014;15(9):846-55.
- 688 33. Kelly B, Pearce EL. Amino Assets: How Amino Acids Support Immunity. *Cell Metab*.
689 2020;32(2):154-75.
- 690 34. Li S, Gao D, Jiang Y. Function, Detection and Alteration of Acylcarnitine Metabolism in
691 Hepatocellular Carcinoma. *Metabolites*. 2019;9(2).

- 692 35. Rosas-Ballina M, Guan XL, Schmidt A, Bumann D. Classical Activation of Macrophages
693 Leads to Lipid Droplet Formation Without de novo Fatty Acid Synthesis. *Front Immunol.*
694 2020;11:131.
- 695 36. Singh A, Sen P. Lipid droplet: A functionally active organelle in monocyte to macrophage
696 differentiation and its inflammatory properties. *Biochim Biophys Acta Mol Cell Biol Lipids.*
697 2021;1866(10):158981.
- 698 37. Aderem AA, Keum MM, Pure E, Cohn ZA. Bacterial lipopolysaccharides, phorbol myristate
699 acetate, and zymosan induce the myristoylation of specific macrophage proteins. *Proceedings of*
700 *the National Academy of Sciences of the United States of America.* 1986;83(16):5817-21.
- 701 38. Jia M, Wang Y, Wang J, Qin D, Wang M, Chai L, et al. Myristic acid as a checkpoint to
702 regulate STING-dependent autophagy and interferon responses by promoting N-myristoylation.
703 *Nat Commun.* 2023;14(1):660.
- 704 39. Tada M, Ichiishi E, Saito R, Emoto N, Niwano Y, Kohno M. Myristic Acid, A Side Chain of
705 Phorbol Myristate Acetate (PMA), Can Activate Human Polymorphonuclear Leukocytes to
706 Produce Oxygen Radicals More Potently than PMA. *J Clin Biochem Nutr.* 2009;45(3):309-14.
- 707 40. Liu B, Zhang M, Zhao J, Zheng M, Yang H. Imbalance of M1/M2 macrophages is linked
708 to severity level of knee osteoarthritis. *Exp Ther Med.* 2018;16(6):5009-14.
- 709 41. Xia T, Fu S, Yang R, Yang K, Lei W, Yang Y, et al. Advances in the study of macrophage
710 polarization in inflammatory immune skin diseases. *J Inflamm (Lond).* 2023;20(1):33.
- 711 42. Zhu W, Yu J, Nie Y, Shi X, Liu Y, Li F, et al. Disequilibrium of M1 and M2 macrophages
712 correlates with the development of experimental inflammatory bowel diseases. *Immunol Invest.*
713 2014;43(7):638-52.
- 714 43. Canales-Herrerias P, Uzzan M, Seki A, Czepielewski RS, Verstockt B, Livanos AE, et al.
715 Gut-associated lymphoid tissue attrition associates with response to anti-alpha4beta7 therapy in
716 ulcerative colitis. *Sci Immunol.* 2024;9(94):eadg7549.
- 717 44. Boden EK, Shows DM, Chiorean MV, Lord JD. Identification of Candidate Biomarkers
718 Associated with Response to Vedolizumab in Inflammatory Bowel Disease. *Dig Dis Sci.*
719 2018;63(9):2419-29.
- 720 45. Soendergaard C, Seidelin JB, Steenholdt C, Nielsen OH. Putative biomarkers of
721 vedolizumab resistance and underlying inflammatory pathways involved in IBD. *BMJ Open*
722 *Gastroenterol.* 2018;5(1):e000208.
- 723 46. Verstockt B, Verstockt S, Veny M, Dehairs J, Arnauts K, Van Assche G, et al. Expression
724 Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic
725 Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases. *Clin Gastroenterol*
726 *Hepatol.* 2020;18(5):1142-51 e10.
- 727 47. Pauwels RWM, de Vries AC, van der Woude CJ. Fecal calprotectin is a reliable marker of
728 endoscopic response to vedolizumab therapy: A simple algorithm for clinical practice. *J*
729 *Gastroenterol Hepatol.* 2020;35(11):1893-901.
- 730 48. Allner C, Melde M, Becker E, Fuchs F, Muhl L, Klenske E, et al. Baseline levels of dynamic
731 CD4(+) T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment
732 in ulcerative colitis: a cohort study. *BMC Gastroenterol.* 2020;20(1):103.
- 733 49. Osterman MT, VanDussen KL, Gordon IO, Davis EM, Li K, Simpson K, et al. Epithelial
734 Cell Biomarkers Are Predictive of Response to Biologic Agents in Crohn's Disease. *Inflamm*
735 *Bowel Dis.* 2021;27(5):677-85.
- 736 50. Holmer AK, Battat R, Dulai PS, Vande Casteele N, Nguyen N, Jain A, et al. Biomarkers
737 are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn's
738 disease. *Therap Adv Gastroenterol.* 2020;13:1756284820971214.
- 739 51. Bertani L, Barberio B, Fornili M, Antonioli L, Zanzi F, Casadei C, et al. Serum oncostatin
740 M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF,
741 but not vedolizumab. *Dig Liver Dis.* 2022;54(10):1367-73.

- 742 52. Gonzalez-Vivo M, Lund Tiirikainen MK, Andreu M, Fernandez-Clotet A, Lopez-Garcia A,
743 Murciano Gonzalo F, et al. Memory T Cell Subpopulations as Early Predictors of Remission to
744 Vedolizumab in Ulcerative Colitis. *Front Med (Lausanne)*. 2022;9:837294.
- 745 53. Gabriels RY, Bourgonje AR, von Martels JZH, Blokzijl T, Weersma RK, Galinsky K, et al.
746 Mucosal Eosinophil Abundance in Non-Inflamed Colonic Tissue Is Associated with Response to
747 Vedolizumab Induction Therapy in Inflammatory Bowel Disease. *J Clin Med*. 2022;11(14).
- 748 54. Abreu MT, Davies JM, Quintero MA, Delmas A, Diaz S, Martinez CD, et al. Transcriptional
749 Behavior of Regulatory T Cells Predicts IBD Patient Responses to Vedolizumab Therapy. *Inflamm*
750 *Bowel Dis*. 2022;28(12):1800-12.
- 751 55. Haglund S, Soderman J, Almer S. Differences in Whole-Blood Transcriptional Profiles in
752 Inflammatory Bowel Disease Patients Responding to Vedolizumab Compared with Non-
753 Responders. *Int J Mol Sci*. 2023;24(6).
- 754 56. Liu J, Fang H, Hong N, Lv C, Zhu Q, Feng Y, et al. Gut Microbiome and Metabonomic
755 Profile Predict Early Remission to Anti-Integrin Therapy in Patients with Moderate to Severe
756 Ulcerative Colitis. *Microbiol Spectr*. 2023;11(3):e0145723.
- 757 57. Roosenboom B, Wahab PJ, Smids C, Meijer J, Kemperman L, Groenen MJM, et al.
758 Mucosal alpha4beta7+ Lymphocytes and MAdCAM+ Venues Predict Response to Vedolizumab
759 in Ulcerative Colitis. *Inflamm Bowel Dis*. 2024;30(6):930-8.
- 760 58. Kim MK, Jo SI, Kim SY, Lim H, Kang HS, Moon SH, et al. PD-1-positive cells contribute
761 to the diagnosis of inflammatory bowel disease and can aid in predicting response to
762 vedolizumab. *Sci Rep*. 2023;13(1):21329.
- 763 59. Danese S, Sandborn WJ, Colombel JF, Vermeire S, Glover SC, Rimola J, et al.
764 Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's
765 Disease. *Gastroenterology*. 2019;157(4):1007-18 e7.
- 766
- 767
- 768

769 **FIGURE LEGENDS**

770

771 **Figure 1. Targeted serum protein analyte levels associated with response to Vedolizumab**
772 **treatment.** Responders to vedolizumab treatment, had higher baseline serum levels of PDGF $\beta\beta$
773 than non-responders **(A)**. In contrast, responders had lower serum levels of SDF-1a at baseline
774 as compared to non-responders **(B)**. In responders, CXCL9/MIG levels increased 61% (FC=1.61)
775 between baseline and week 14, whereas there was a 66% decrease (FC=0.44) in non-responders
776 **(C)**. In contrast, serum levels of IL-10 decreased 15% (FC=0.85) in responders, with a 27%
777 increase (FC=1.27) in non-responders **(D)**. Filled symbols are for individuals where samples were
778 only available at baseline. All plots shown are for “UC”. See also **Table S2**.

779

780 **Figure 2. Targeted serum metabolite levels associated with response to Vedolizumab**
781 **treatment.**





782 A selected set of analytes that were found to be associated with response at 14 weeks are
783 presented. Elevated baseline levels of the amino acid lysine **(A)** and the organic acid lactate **(B)**
784 were associated with response to treatment in patients with UC ($P=2.1\times 10^{-3}$ and $P=1.31\times 10^{-3}$,
785 respectively). We also observed that ~2-fold increase in serum levels of the organic acid citrate
786 was associated with response in patients with CD **(C)**. Baseline serum levels of multiple acyl
787 carnitines, including AC 3:0 were also associated ($P=2.9\times 10^{-3}$) with response **(D)**. Filled symbols
788 are for individuals where samples were only available at baseline. All plots shown are for “UC”,
789 except for citrate (C), where the plot is shown for “CD”. See also **Table S3**.

790

791 **Figure 3. Untargeted serum LC-MS-based lipidomic analyses.**

792 We identified 107 lipid features that were significantly ($P<0.05$) associated to response **(A)**. Colors
793 in the volcano plot represent the 18 clusters of metabolites identified by WGCNA. The first
794 component (PC1) from the PCA of the 1111 lipid features was significantly associated ($P=0.017$)
795 with response **(B)**. This PC1 was not only associated with response to therapy but was also
796 associated with BMI ($P=5.1\times 10^{-5}$) **(C)**; dotted lines represent SE of loess fit. Importantly, we did
797 not detect any significant association between BMI and response. The PCA loadings value for
798 each lipid feature was plotted, illustrating that PC1 is primarily driven by the “blue” WGCNA
799 cluster, which is also associated to response ($P=5.8\times 10^{-3}$) **(D)**. We also found an opposite impact
800 for features from another module (named turquoise), which was not significantly associated to
801 response to therapy ($P=0.44$). See also **Table S4** and **S5**.

802



medRxiv preprint doi: <https://doi.org/10.1101/2024.09.19.24314034>; this version posted September 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 1





A**B****C****D**

Figure 3




Figure 2